Advertisement

Adenosine Injection

[20 May 2015]

Products Affected - Description

Diagnostic Adjunct
Adenosine Injection, Sagent
3 mg/mL, 30 mL vial, single count (NDC 25021-0307-30)
 
Adenoscan Injection, Astellas
3 mg/mL, 30 mL vial, 10 count (NDC 00469-0871-30) - discontinued
3 mg/mL, 20 mL vial, 10 count (NDC 00469-0871-20) - discontinued

Use in Paroxysmal Supraventricular Tachycardia

Adenosine Injection, Sagent
3 mg/mL, 2 mL vial, 10 count (NDC 25021-0301-02)
3 mg/mL, 4 mL vial, 10 count (NDC 25021-0301-04)

Adenosine Injection, West-Ward
3 mg/mL, 2 mL vial, 10 count (NDC 00641-6113-10)

Reason for the Shortage

  • Astellas discontinued Adenoscan in April 2015. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
  • Ben Venue has stopped production in its plant in Bedford, Ohio and closed in July 2014.
  • Sagent has adenosine vials on shortage due to increased demand..
  • Teva has discontinued their adenosine injection.
  • West-Ward could not provide a reason for the shortage. 
  • Wockhardt discontinued their adenosine 3 mg/mL 2 mL and 4 mL syringes.

Available Products

Adenosine Injection, Akorn
3 mg/mL, 30 mL vial, single count (NDC 17478-0544-30)
3 mg/mL, 20 mL vial, single count (NDC 17478-0544-20)

Adenosine Injection, Sagent
3 mg/mL, 20 mL vial, single count (NDC 25021-0307-20)

Use in Paroxysmal Supraventricular Tachycardia
Adenosine Injection, Akorn
3 mg/mL, 2 mL vial, 10 count (NDC 17478-0542-02)
3 mg/mL, 2 mL vial, 25 count (NDC 17478-0542-25)
 
Adenosine Injection, Fresenius Kabi
3 mg/mL, 2 mL vial, 10 count (NDC 63323-0651-02)
3 mg/mL, 4 mL vial, 10 count (NDC 63323-0651-04)

Adenosine Injection, Sagent
3 mg/mL, 2 mL prefilled syringe, 10 count (NDC 25021-0301-67)
3 mg/mL, 4 mL prefilled syringe, 10 count (NDC 25021-0301-68)

Adenocard Injection, Astellas
3 mg/mL, 2 mL prefilled syringe, 10 count (NDC 00469-8234-12)
3 mg/mL, 4 mL prefilled syringe, 10 count (NDC 00469-8234-14)

Estimated Resupply Dates

Diagnostic Adjunct
  • Sagent has adenosine 3 mg/mL 30 mL vials on back order and the company cannot estimate a release date.
Use in Paroxysmal Supraventricular Tachycardia
  • Sagent has adenosine 3 mg/mL 2 mL and 4 mL vials on back order and the company cannot estimate a release date.
  • West-Ward has adenosine 3 mg/mL 2 mL vials on back order and the company cannot estimate a release date.

Related Shortages

Updated

May 20, April 16 and 27, March 4, 5, 12, 20, and 27, February 20, January 9, 26, and 29, 2015; December 15, November 17, September 8 and 23, August 4, July 3 and 18, May 7, 13, 15, and 22, 2014; April 1, 24, and 25, March 4, 14, 17, and 28, February 12 and 21, January 14, 2014; December 11, October 18, September 16, August 15 and 29, July 18, June 18, May 13 and 15, April 11, March 1 and 13, February 13, and January 25, 2013; December 21 and 28, November 19, 2012, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement